A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

BACKGROUND: We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). PATIENTS AND METHODS: We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-...

Descripción completa

Detalles Bibliográficos
Autores principales: Galffy, G., Lugowska, I., Poddubskaya, E.V., Cho, B.C., Ahn, M.-J., Han, J.-Y., Su, W.-C., Hauke, R.J., Dyar, S.H., Lee, D.H., Serwatowski, P., Estelles, D.L., Holden, V.R., Kim, Y.J., Vladimirov, V., Horvath, Z., Ghose, A., Goldman, A., di Pietro, A., Wang, J., Murphy, D.A., Alhadab, A., Laskov, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265612/
https://www.ncbi.nlm.nih.gov/pubmed/37141847
http://dx.doi.org/10.1016/j.esmoop.2023.101173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265612/
https://www.ncbi.nlm.nih.gov/pubmed/37141847
http://dx.doi.org/10.1016/j.esmoop.2023.101173

Ejemplares similares